The estimated Net Worth of Ventures Vi Lprmv Vi, L.L.C... is at least $890 Tisíc dollars as of 16 March 2016. Ventures C owns over 400,000 units of Cara Therapeutics Inc stock worth over $889,737 and over the last 9 years Ventures sold CARA stock worth over $0.
Ventures has made over 1 trades of the Cara Therapeutics Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently Ventures bought 400,000 units of CARA stock worth $1,948,000 on 16 March 2016.
The largest trade Ventures's ever made was buying 400,000 units of Cara Therapeutics Inc stock on 16 March 2016 worth over $1,948,000. On average, Ventures trades about 400,000 units every 0 days since 2016. As of 16 March 2016 Ventures still owns at least 3,068,057 units of Cara Therapeutics Inc stock.
You can see the complete history of Ventures C stock trades at the bottom of the page.
Over the last 11 years, insiders at Cara Therapeutics Inc have traded over $25,200,591 worth of Cara Therapeutics Inc stock and bought 1,874,453 units worth $19,406,983 . The most active insiders traders include Edward Hurwitz, Martin Vogelbaum a Ventures Vi Lprmv Vi, L.L.C.... On average, Cara Therapeutics Inc executives and independent directors trade stock every 19 days with the average trade being worth of $5,343. The most recent stock trade was executed by Christopher Posner on 1 August 2024, trading 4,149 units of CARA stock currently worth $1,452.
cara therapeutics is an emerging biotechnology company focused on developing novel therapeutics to treat pain, inflammation and pruritus. cara possesses both near-term clinical development opportunities combined with proprietary approaches to developing first-in-class novel therapeutics. cara's most advanced patented compound, cr845, is currently undergoing clinical testing for acute pain and uremic pruritus. this compound possesses analgesic, anti-inflammatory and antipruritic activities appropriate for multiple therapeutic applications. in addition, cara aims to develop a future pipeline of first-in-class molecules at novel analgesic and anti-inflammatory targets using its proprietary drug screening technology.
Cara Therapeutics Inc executives and other stock owners filed with the SEC include: